Glycogen synthase kinase 3 (GSK3), a serine/threonine kinase, and its expression in CRC associates with the regulation of cell cycle, cancer proliferation, and apoptosis [29], thus making it a potential biomarker for therapeutic development in CRC [31,32,33]. Here, MARK2 is linked to colorectal carcinoma.